Assessment of rheumatologic tolerability of letrozole in postmenopausal patients with hormone receptor positive breast cancer having discontinued anastrozole adjuvant treatment due to musculoskeletal disorders
Latest Information Update: 27 Feb 2017
Price :
$35 *
At a glance
- Drugs Letrozole (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- Sponsors Novartis
- 01 Oct 2008 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.
- 01 Oct 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jul 2007 New trial record.